Literature DB >> 25489080

Disruption of the Na+ ion binding site as a mechanism for positive allosteric modulation of the mu-opioid receptor.

Kathryn E Livingston1, John R Traynor2.   

Abstract

Positive allosteric modulation of the mu-opioid receptor (MOPr), the site of action of all clinically used opioids, represents a potential approach for the management of pain. We recently reported on positive allosteric modulators of MOPr (mu-PAMs), a class A G protein coupled receptor (GPCR). This study was designed to examine the mechanism of allostery by comparing the degree to which opioid ligand structure governs modulation. To do this we examined the interaction of the mu-PAM, BMS-986122, with a chemically diverse range of MOPr orthosteric ligands. Generally, for full agonists BMS-986122 enhanced the binding affinity and potency to activate G protein with no alteration in the maximal effect. In contrast, lower efficacy agonists including morphine were insensitive to alterations in binding affinity and showed little to no change in potency to stimulate G protein. Instead, there was an increase in maximal G protein stimulation. Antagonists were unresponsive to the modulatory effects of BMS-986122. Sodium is a known endogenous allosteric modulator of MOPr and alters orthosteric agonist affinity and efficacy. The sensitivity of an orthosteric ligand to BMS-986122 was strongly correlated with its sensitivity to NaCl. In addition, BMS-986122 decreased the ability of NaCl to modulate agonist binding in an allosteric fashion. Overall, BMS-986122 displayed marked probe dependence that was based upon the efficacy of the orthosteric ligand and can be explained using the Monod-Wyman-Changeux two-state model of allostery. Furthermore, disruption of the Na(+) ion binding site may represent a common mechanism for allosteric modulation of class A GPCRs.

Entities:  

Keywords:  GTPgammaS; endogenous opioids; ligand binding; opiates; receptor states

Mesh:

Substances:

Year:  2014        PMID: 25489080      PMCID: PMC4280615          DOI: 10.1073/pnas.1415013111

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  45 in total

1.  A Monod-Wyman-Changeux mechanism can explain G protein-coupled receptor (GPCR) allosteric modulation.

Authors:  Meritxell Canals; J Robert Lane; Adriel Wen; Peter J Scammells; Patrick M Sexton; Arthur Christopoulos
Journal:  J Biol Chem       Date:  2011-11-15       Impact factor: 5.157

Review 2.  Allosteric modulation of G protein-coupled receptors: a pharmacological perspective.

Authors:  Peter Keov; Patrick M Sexton; Arthur Christopoulos
Journal:  Neuropharmacology       Date:  2010-07-15       Impact factor: 5.250

3.  Conformational changes in the G protein Gs induced by the β2 adrenergic receptor.

Authors:  Ka Young Chung; Søren G F Rasmussen; Tong Liu; Sheng Li; Brian T DeVree; Pil Seok Chae; Diane Calinski; Brian K Kobilka; Virgil L Woods; Roger K Sunahara
Journal:  Nature       Date:  2011-09-28       Impact factor: 49.962

Review 4.  Refining efficacy: allosterism and bias in G protein-coupled receptor signaling.

Authors:  Louis M Luttrell; Terry P Kenakin
Journal:  Methods Mol Biol       Date:  2011

5.  Probe dependence in the allosteric modulation of a G protein-coupled receptor: implications for detection and validation of allosteric ligand effects.

Authors:  Celine Valant; Christian C Felder; Patrick M Sexton; Arthur Christopoulos
Journal:  Mol Pharmacol       Date:  2011-10-11       Impact factor: 4.436

6.  Allosteric modulator ORG27569 induces CB1 cannabinoid receptor high affinity agonist binding state, receptor internalization, and Gi protein-independent ERK1/2 kinase activation.

Authors:  Kwang H Ahn; Mariam M Mahmoud; Debra A Kendall
Journal:  J Biol Chem       Date:  2012-02-16       Impact factor: 5.157

7.  Endogenous regulators of G protein signaling differentially modulate full and partial mu-opioid agonists at adenylyl cyclase as predicted by a collision coupling model.

Authors:  M J Clark; J J Linderman; J R Traynor
Journal:  Mol Pharmacol       Date:  2008-02-19       Impact factor: 4.436

8.  Selective activation of the M1 muscarinic acetylcholine receptor achieved by allosteric potentiation.

Authors:  Lei Ma; Matthew A Seager; Matthew Seager; Marion Wittmann; Marlene Jacobson; Denise Bickel; Maryann Burno; Keith Jones; Valerie Kuzmick Graufelds; Guangping Xu; Michelle Pearson; Alexander McCampbell; Renee Gaspar; Paul Shughrue; Andrew Danziger; Christopher Regan; Rose Flick; Danette Pascarella; Susan Garson; Scott Doran; Constantine Kreatsoulas; Lone Veng; Craig W Lindsley; William Shipe; Scott Kuduk; Cyrille Sur; Gene Kinney; Guy R Seabrook; William J Ray
Journal:  Proc Natl Acad Sci U S A       Date:  2009-08-26       Impact factor: 11.205

9.  Structure-function studies of allosteric agonism at M2 muscarinic acetylcholine receptors.

Authors:  Lauren T May; Vimesh A Avlani; Christopher J Langmead; Hugh J Herdon; Martyn D Wood; Patrick M Sexton; Arthur Christopoulos
Journal:  Mol Pharmacol       Date:  2007-05-24       Impact factor: 4.436

10.  Crystal structure of the µ-opioid receptor bound to a morphinan antagonist.

Authors:  Aashish Manglik; Andrew C Kruse; Tong Sun Kobilka; Foon Sun Thian; Jesper M Mathiesen; Roger K Sunahara; Leonardo Pardo; William I Weis; Brian K Kobilka; Sébastien Granier
Journal:  Nature       Date:  2012-03-21       Impact factor: 49.962

View more
  24 in total

1.  Discovery, synthesis, and molecular pharmacology of selective positive allosteric modulators of the δ-opioid receptor.

Authors:  Neil T Burford; Kathryn E Livingston; Meritxell Canals; Molly R Ryan; Lauren M L Budenholzer; Ying Han; Yi Shang; John J Herbst; Jonathan O'Connell; Martyn Banks; Litao Zhang; Marta Filizola; Daniel L Bassoni; Tom S Wehrman; Arthur Christopoulos; John R Traynor; Samuel W Gerritz; Andrew Alt
Journal:  J Med Chem       Date:  2015-05-07       Impact factor: 7.446

2.  The δ-opioid receptor positive allosteric modulator BMS 986187 is a G-protein-biased allosteric agonist.

Authors:  M Alexander Stanczyk; Kathryn E Livingston; Louise Chang; Zara Y Weinberg; Manojkumar A Puthenveedu; John R Traynor
Journal:  Br J Pharmacol       Date:  2019-04-14       Impact factor: 8.739

Review 3.  Allostery at opioid receptors: modulation with small molecule ligands.

Authors:  Kathryn E Livingston; John R Traynor
Journal:  Br J Pharmacol       Date:  2017-06-07       Impact factor: 8.739

4.  Identification of Positive Allosteric Modulators of the D1 Dopamine Receptor That Act at Diverse Binding Sites.

Authors:  Kathryn D Luderman; Jennie L Conroy; R Benjamin Free; Noel Southall; Marc Ferrer; Marta Sanchez-Soto; Amy E Moritz; Blair K A Willette; Tim J Fyfe; Prashi Jain; Steve Titus; Lisa A Hazelwood; Jeffrey Aubé; J Robert Lane; Kevin J Frankowski; David R Sibley
Journal:  Mol Pharmacol       Date:  2018-08-01       Impact factor: 4.436

Review 5.  An overview of recent molecular dynamics applications as medicinal chemistry tools for the undruggable site challenge.

Authors:  Ugo Perricone; Maria Rita Gulotta; Jessica Lombino; Barbara Parrino; Stella Cascioferro; Patrizia Diana; Girolamo Cirrincione; Alessandro Padova
Journal:  Medchemcomm       Date:  2018-04-19       Impact factor: 3.597

6.  G protein-coupled receptors of class A harness the energy of membrane potential to increase their sensitivity and selectivity.

Authors:  Daria N Shalaeva; Dmitry A Cherepanov; Michael Y Galperin; Gert Vriend; Armen Y Mulkidjanian
Journal:  Biochim Biophys Acta Biomembr       Date:  2019-08-23       Impact factor: 3.747

Review 7.  Harnessing Ion-Binding Sites for GPCR Pharmacology.

Authors:  Barbara Zarzycka; Saheem A Zaidi; Bryan L Roth; Vsevolod Katritch
Journal:  Pharmacol Rev       Date:  2019-10       Impact factor: 25.468

Review 8.  Recent Advances in the Realm of Allosteric Modulators for Opioid Receptors for Future Therapeutics.

Authors:  Michael Remesic; Victor J Hruby; Frank Porreca; Yeon Sun Lee
Journal:  ACS Chem Neurosci       Date:  2017-04-07       Impact factor: 4.418

9.  Pharmacologic Evidence for a Putative Conserved Allosteric Site on Opioid Receptors.

Authors:  Kathryn E Livingston; M Alexander Stanczyk; Neil T Burford; Andrew Alt; Meritxell Canals; John R Traynor
Journal:  Mol Pharmacol       Date:  2017-12-12       Impact factor: 4.436

10.  Homology modeling, docking, and molecular dynamics simulation of the receptor GALR2 and its interactions with galanin and a positive allosteric modulator.

Authors:  Wen-Qi Hui; Qi Cheng; Tian-Yu Liu; Qin Ouyang
Journal:  J Mol Model       Date:  2016-03-28       Impact factor: 1.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.